Kevin Perraud

654 total citations · 1 hit paper
6 papers, 516 citations indexed

About

Kevin Perraud is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Kevin Perraud has authored 6 papers receiving a total of 516 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 2 papers in Pulmonary and Respiratory Medicine and 2 papers in Hepatology. Recurrent topics in Kevin Perraud's work include Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Radiopharmaceutical Chemistry and Applications (1 paper). Kevin Perraud is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Radiopharmaceutical Chemistry and Applications (1 paper). Kevin Perraud collaborates with scholars based in Switzerland, France and United States. Kevin Perraud's co-authors include Bruno Daniele, Arndt Vogel, Markus Peck‐Radosavljevic, Ho Yeong Lim, Stéphane Cattan, Andrew X. Zhu, Li‐Tzong Chen, Junji Furuse, Étienne Dorval and Armando Santoro and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and European Journal of Nuclear Medicine and Molecular Imaging.

In The Last Decade

Kevin Perraud

6 papers receiving 510 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

2014 449 citations Andrew X. Zhu, Masatoshi Kudo et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kevin Perraud Switzerland	4	346	167	144	136	133	6	516
Neus Llarch Spain	9	440 1.3×	137 0.8×	52 0.4×	201 1.5×	124 0.9×	23	518
Amani Asnacios France	11	386 1.1×	184 1.1×	119 0.8×	384 2.8×	248 1.9×	14	726
Eleni Vrettou Greece	15	145 0.4×	119 0.7×	147 1.0×	129 0.9×	304 2.3×	33	562
Hiroaki Hagihara Japan	13	253 0.7×	64 0.4×	144 1.0×	159 1.2×	72 0.5×	25	427
G.K. Abou-Alfa United States	11	266 0.8×	99 0.6×	108 0.8×	101 0.7×	179 1.3×	30	467
Diyang Xie China	8	436 1.3×	113 0.7×	106 0.7×	215 1.6×	150 1.1×	10	632
Sara Torrecilla Spain	6	212 0.6×	82 0.5×	252 1.8×	82 0.6×	121 0.9×	10	512
Judit Peix Spain	7	298 0.9×	119 0.7×	307 2.1×	133 1.0×	157 1.2×	10	657
Silvija Kraljevic United States	8	157 0.5×	83 0.5×	67 0.5×	40 0.3×	178 1.3×	15	327

Countries citing papers authored by Kevin Perraud

Since Specialization

Citations

This map shows the geographic impact of Kevin Perraud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Perraud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Perraud more than expected).

Fields of papers citing papers by Kevin Perraud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Perraud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Perraud. The network helps show where Kevin Perraud may publish in the future.

Co-authorship network of co-authors of Kevin Perraud

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Perraud. A scholar is included among the top collaborators of Kevin Perraud based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Perraud. Kevin Perraud is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Gaze, Mark N., Daria Handkiewicz-Junak, Raquel Hladun, et al.. (2025). Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study. European Journal of Nuclear Medicine and Molecular Imaging. 52(11). 4001–4015. 6 indexed citations

2.

N., Kim, Nabil Adra, Rohan Garje, et al.. (2022). Exposure-adjusted safety analyses of the VISION phase 3 trial of ¹⁷⁷Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 40(6_suppl). 85–85. 1 indexed citations

3.

Mauro, Michael J., Fabian Lang, Dong-Wook Kim, et al.. (2018). Clinical Development of Asciminib (ABL001): A Randomized Phase 3 Study of Asciminib vs Bosutinib in Patients with Chronic Myeloid Leukemia (CML). Clinical Lymphoma Myeloma & Leukemia. 18. S223–S223. 1 indexed citations

4.

Zhu, Andrew X., Masatoshi Kudo, Eric Assénat, et al.. (2014). EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib.. Journal of Clinical Oncology. 32(3_suppl). 172–172. 33 indexed citations

5.

Zhu, Andrew X., Masatoshi Kudo, Eric Assénat, et al.. (2014). Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib. JAMA. 312(1). 57–57. 449 indexed citations breakdown →

6.

Jones, Alison, Mary O’Brien, Harald Sommer, et al.. (2009). Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemotherapy and Pharmacology. 65(4). 755–763. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact